Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America. Current treatments include benznidazole and nifurtimox, which are most effective in the acute phase of the disease but less so in the chronic phase, often with significant side effects. Here, using the available literature, we summarize the progress in vaccine development and new treatments that promise to reduce CD incidence and improve the quality of life for those at risk, particularly in endemic regions. New treatment options, such as posaconazole and fexinidazole, are being explored to improve efficacy and reduce adverse effects. Vaccine development for CD remains a high priority. The complex life stages and genetic diversity of Trypanosoma cruzi present challenges, but several promising vaccine candidates are under investigation. These efforts focus on stimulating a protective immune response through various innovative approaches.

Chagas disease (CD), caused by the parasite Trypanosoma cruzi, remains one of the most important neglected tropical diseases. Historically confined to rural areas of Latin America, the disease has now become a global health challenge due to increased migration, urbanization, and ecological changes. This review explores how patterns of transmission and endemicity have evolved, emphasizing the emergence of new geographic hotspots and non-traditional routes of transmission, such as congenital and oral infections. We integrate evidence from ecological studies showing how deforestation, urban sprawl, and climate change are reshaping vector habitats and influencing the spread of triatomine insects. Furthermore, we highlight advances made between 2020 and 2025 in key research areas, including vector genomics and climate-based predictive mapping, as well as digital surveillance strategies that leverage machine learning and citizen science. These innovations provide valuable insights for predicting future risks and improving disease control. By linking global epidemiological trends, ecological drivers, and cutting-edge scientific advances, this review underscores the urgent need for integrated, collaborative strategies to prevent further spread and to protect vulnerable populations worldwide.

Chagas disease, caused by Trypanosoma cruzi, remains a significant global health challenge, particularly in the molecular diagnostics of low parasitemia during the chronic phase. This highlights the critical need for enhanced diagnostic methodologies. In response, this study evaluates the effectiveness of an automated magnetic beads-based DNA extraction method in improving the molecular diagnosis of Chagas disease compared to the traditional silica column-based extraction. Accordingly, this research seeks to enhance the DNA yield, purity, and sensitivity of real-time PCR (qPCR) assays for detecting T. cruzi satDNA. Blood samples spiked with guanidine–EDTA solution and varying concentrations of T. cruzi were used to compare the two extraction methods. The results indicated that the magnetic bead-based method outperformed the silica column in terms of DNA concentration, purity, and earlier detection of T. cruzi satDNA. Although both methods had similar limits of detection at a 95% confidence interval, the magnetic bead-based approach demonstrated higher sensitivity and reproducibility, particularly in low-parasitemia samples. The findings suggest that the magnetic beads-based DNA extraction method offers a more reliable, faster, and more sensitive alternative for diagnosing chronic Chagas disease, potentially improving clinical outcomes by enabling more accurate and earlier parasite detection.